Southern Research Expands Capabilities with Acquisition of BioCryst Pharmaceuticals Bioanalytical Lab Unit

BIRMINGHAM, Ala., Oct. 14 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that it is acquiring the bioanalytical laboratory assets and bioanalytical personnel of BioCryst Pharmaceuticals. Terms of the agreement were not disclosed.

This acquisition will allow Southern Research to expand its existing bioanalytical laboratory services, especially in the area of clinical trials support.

"We are happy to have this opportunity to expand our bioanalytical services and to offer some BioCryst employees an opportunity to join our team at Southern Research," said Andrew Penman, Ph.D., vice president of Drug Development at Southern Research. "This offer will also keep these scientists and their families in Birmingham, which is important to industry growth here."

The bioanalytical lab personnel will continue working in the BioCryst research facility in Birmingham until they can be relocated to Southern Research's Southside Birmingham campus some time early next year.

For more information about Southern Research's preclinical drug discovery and development services, please contact [email protected]

ABOUT SOUTHERN RESEARCH

Southern Research Institute is a not-for-profit 501(c) 3 scientific research organization founded in 1941 that conducts preclincal drug discovery and development, advanced engineering research in materials, systems development, and environment and energy research. More than 550 scientific and engineering team members support clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental and energy industries. Southern Research is headquartered in Birmingham, Ala., with facilities in Wilsonville, Ala., Frederick, Md., and Durham, NC and offices in Huntsville, Ala., New Orleans, La., Washington, DC and Kiev, Ukraine.  For more information see www.SouthernResearch.org.

Suggested Articles

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.

OnKure's HDAC inhibitor overcame resistance to anti-PD-1 therapy in mouse models of B-cell lymphoma, University of Colorado researchers found.